• ABOUT DRY EYE
  • Symptoms, Causes, and Diagnosis of Dry Eye
  • Treatments for Dry Eye
    • Artificial Tears
    • Prescription Options
    • Other Patient Options
• ABOUT LACRISERT^®
  • How LACRISERT^® Works
  • The Benefits of LACRISERT^®
  • Writing LACRISERT^®
  • How Patients Use LACRISERT^®
  • LACRISERT^® Efficacy Data
  • Patient Testimonials
• RESOURCES FOR YOU + YOUR PATIENTS
  • LACRISERT^® Sample Request and Material Order Form
  • Customizable Tip Sheet
  • Valeant Patient Savings Program
  • Valeant Patient Assistance Program
  • Learn More About LACRISERT^®
  • Valuable Links
  • Presentations
• FAQs

Treatments for Dry Eye

Prescription Options

Two prescription options for your moderate to severe Dry Eye patients are:

• LACRISERT^®—A Dry Eye therapy that has been approved and used for over 25 years.¹ This once-daily,* slow-release insert improves tear film break-up time and relieves Dry Eye symptoms by helping the lacrimal glands, eye lids, and ocular surface to retain a more stable tear film for a longer period of time.^2,3 LACRISERT^® is the only prescription eye insert available in the United States
• Cyclosporine ophthalmic emulsion, 0.05%—A twice-a-day eyedrop that has been approved by the FDA for the treatment of ocular inflammation associated with keratoconjunctivitis sicca.^4,5 While LACRISERT^® has not been studied with cyclosporine ophthalmic emulsion, ophthalmologists have reported that they have successfully used the 2 therapies in combination.

Click here to see if LACRISERT^® is the right treatment option for your moderate to severe Dry Eye patients.

Click the following links to learn more about Dry Eye treatments:

• Artificial Tears
• Other Patient Options

Indications and Usage

LACRISERT^® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT^® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT^® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

LACRISERT^® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT^® should be carefully followed. If improperly placed, LACRISERT^® may result in corneal abrasion. Because LACRISERT^® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT^®.

The following adverse reactions have been reported, but were in most instances, mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

*For most Dry Eye sufferers, one LACRISERT^® inserted in each eye in the morning lasts the entire day. But some people may need to use it twice a day for symptom relief.²

References: 1. Data on File. Aton Pharma, Inc. 2. Lacrisert [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2007. 3. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007;5(2):75-92. Available at: http://www.tearfilm.org/dewsreport. Accessed January 5, 2009. 4. Drug Approvals–R. U.S. Food & Drug Administration Web site. Available at: www.fda.gov/cder/approval/r.htm. Accessed: January 9, 2009. 5. Restasis 0.05% [prescribing information]. Irvine, CA:Allergan, Inc; 2008.